System and method for aggregation and autologous use of alpha 2m molecules to treat respiratory conditions

A kit for treating a respiratory condition of a patient with at least Alpha-2 Macroglobulin (α2M) molecules, the kit comprising:

• at least one separator tube, wherein each separator tube of the at least one separator tube comprises:
• an elongate transparent tube that defines an opening at one end that is sealed with a cap that is penetrable to receive whole blood;
• and
• an amount of separator gel disposed within the separator tube to cooperate with a first centrifugal force exerted on the separator tube for a first period of time during a first centrifuging stage to separate platelet poor plasma (PPP) containing α2M molecules from other components of the whole blood;
• at least one aggregator, wherein each aggregator of the at least one aggregator comprises:
• a filter;
• a first cylinder defined by a first cylindrical wall having a first end that is configured to be closable with a septum cap that is penetrable to receive the PPP following the first centrifuging stage, and having a second end that is closed with the filter;
• and
• a second cylinder defined by a second cylindrical wall having a first end that is closed where the second cylindrical wall narrows to form a conically-shaped end portion, and having a second end that defines an opening that is configured to be coupled to the filter in a manner that causes a first interior volume of the first cylinder and a second interior volume of the second cylinder to be separated by the filter, wherein the filter is configured to cooperate with a second centrifugal force exerted on the aggregator for a second period of time during a second centrifuging stage to filter waste plasma from the PPP to generate an aggregate of the α2M molecules;
• a transfer device, comprising:
• a separator tube port configured to receive each separator tube of the at least one separator tube, one at a time, wherein the separator tube port comprises at least one hollow needle configured to penetrate the cap of each separator tube to couple the separator tube to a syringe port of the transfer device;
• and
• the syringe port configured to receive an end connector of a transfer syringe that is configured to be coupled to a transfer needle, wherein, following the first centrifuging stage and prior to the second centrifuging stage:
• while each separator tube of the at least one separator tube is coupled to the separator tube port, a plunger of the transfer syringe is operable to withdraw at least some of the PPP from within the separator tube and into the transfer syringe through the transfer device;
• and
• following the transfer of PPP from each separator tube of the at least one separator tube, and with the transfer needle coupled to the end connector to penetrate the septum cap of each aggregator of the at least one aggregator, the plunger of the transfer syringe is operable to inject the PPP within the transfer syringe into the at least one aggregator;
• and
• a nebulizer configured to be provided with the aggregate, and to administer the aggregate to the patient via inhalation.